Author

Tina Tan

ORCID 0009-0004-5574-6392Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Synthetic Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 1

Frequent Co-Authors

Aaron Edward FosteriD· 2 shared Bradley HammersoniD· 2 shared Brian D. WeitzneriD· 2 shared David S. Clausen· 2 shared Howell F. MoffettiD· 2 shared Jared Louis Hammer· 2 shared Jerry C. Chen· 2 shared John T. Crowl· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSynthetic Biology

Aaron Edward FosterORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Rationally Designed Transgene Drives CAR T Functional Persistence and Durable Regression of Solid Tumors

Rupesh H. Amin, Kevin G. Haworth, Howell F. Moffett, Jerry C. Chen, Lisa Park, Jason K. Yokoyama, Allan L. Wang, Leah J. Tait, Maria M. Steele, John T. Crowl, Thaddeus M. Davenport, Joseph DeSautelle, Jared Louis Hammer, Willimark Obenza, Vanessa R. Montoya, , Aaron Edward Foster

This paper designs a transgene that enhances CAR T cell persistence and tumor regression by integrating multiple engineered technologies in solid tumor models.

bioRxiv · Sep 24, 2026 · PreprintSynthetic Biology

A Dynamically Regulated Designed IL-2 for Tumor-localized Signaling

Howell F. Moffett, Brian D. Weitzner, Michelle M. Lissner, Thaddeus M. Davenport, Kevin G. Haworth, Erika T. Hayes, Robert A. Langan, Leah J. Tait, Willimark Obenza, Bradley Hammerson, Robin L. Kirkpatrick, Laura E. Baker, John T. Crowl, Jared Louis Hammer, Tina Tan, , Marc J. Lajoie

This paper designs a dynamically regulated IL-2 variant that enhances tumor-specific immune responses while reducing systemic toxicity.

bioRxiv · Sep 22, 2026 · PreprintSynthetic Biology